Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | FGR | P09769 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | FER | P16591 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.57 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.57 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16737365 | 1.00 | SYK (0.63) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16737363 | 1.00 | SYK (0.63) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16737950 | 0.90 | SYK (0.55) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16737952 | 0.90 | SYK (0.55) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16737954 | 0.90 | SYK (0.55) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL20377638 | 0.89 | SYK (0.64) | SYK | |
| SCHEMBL20377617 | 0.89 | SYK (0.64) | SYK | |
| SCHEMBL16737842 | 0.89 | SYK (0.64) | SYK | |
| SCHEMBL16737324 | 0.87 | SYK (0.72) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16737906 | 0.84 | SYK (0.65) | SYKJAK2NTRK1FYNFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | SYK 1/4885JAK2 11/4885NTRK1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.